Rosenman Marc B, Decker Brian, Levy Kenneth D, Holmes Ann M, Pratt Victoria M, Eadon Michael T
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Value Health. 2017 Jan;20(1):54-59. doi: 10.1016/j.jval.2016.08.727. Epub 2016 Oct 21.
Implementing new programs to support precision medicine in clinical settings is a complex endeavor. We describe challenges and potential solutions based on the Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health-one of six sites supported by the Implementing GeNomics In pracTicE network grant of the National Institutes of Health/National Human Genome Research Institute. INGenious is an implementation of a panel of genomic tests.
We conducted a descriptive case study of the implementation of this pharmacogenomics program, which has a wide scope (14 genes, 27 medications) and a diverse population (patients who often have multiple chronic illnesses, in a large urban safety-net hospital and its outpatient clinics).
We placed the clinical pharmacogenomics implementation challenges into six categories: patient education and engagement in care decision making; clinician education and changes in standards of care; integration of technology into electronic health record systems; translational and implementation sciences in real-world clinical environments; regulatory and reimbursement considerations, and challenges in measuring outcomes. A cross-cutting theme was the need for careful attention to workflow. Our clinical setting, a safety-net health care system, presented some distinctive challenges. Patients often had multiple chronic illnesses and sometimes were taking more than one pharmacogenomics-relevant medication. Reaching patients for recruitment or follow-up was another challenge.
New, large-scale endeavors in health care are challenging. A description of the challenges that we encountered and the approaches that we adopted to address them may provide insights for those who implement and study innovations in other health care systems.
在临床环境中实施支持精准医学的新项目是一项复杂的工作。我们基于印第安纳基因组学实施项目:为弱势群体提供机会(INGenious)计划,描述了相关挑战和潜在解决方案。INGenious计划是美国国立卫生研究院/国家人类基因组研究所的“实践中实施基因组学”网络资助项目所支持的六个项目点之一,位于埃斯凯纳齐健康中心。INGenious计划是一组基因组检测的实施方案。
我们对这个药物基因组学项目的实施情况进行了描述性案例研究,该项目范围广泛(涉及14个基因、27种药物),且研究对象多样(来自一家大型城市安全网医院及其门诊诊所,患有多种慢性病的患者)。
我们将临床药物基因组学实施过程中的挑战分为六类:患者教育以及参与护理决策;临床医生教育以及护理标准的变化;将技术整合到电子健康记录系统;真实世界临床环境中的转化和实施科学;监管和报销方面的考虑,以及衡量结果的挑战。一个贯穿各方面的主题是需要密切关注工作流程。我们的临床环境,即一个安全网医疗系统,带来了一些独特的挑战。患者通常患有多种慢性病,有时服用不止一种与药物基因组学相关的药物。联系患者进行招募或随访是另一个挑战。
医疗保健领域新的大规模项目具有挑战性。对我们遇到的挑战以及我们为应对这些挑战所采用的方法进行描述,可能会为那些在其他医疗系统中实施和研究创新的人提供见解。